University of East Anglia Featured PhD Programmes
Sheffield Hallam University Featured PhD Programmes
University of Nottingham Featured PhD Programmes
"breast"×
10 miles

breast PhD Projects, Programs & Scholarships

We have 63 breast PhD Projects, Programs & Scholarships

  • "breast" ×
  • clear all
Order by 
Showing 1 to 15 of 63
  The role of the microenvironment in regulating breast cancer metastatic colonisation
  Dr R Clarke, Dr Ciara O'Brien, Dr R Eyre
Applications accepted all year round

Funding Type

PhD Type

The metastatic spread of breast cancer cells and their colonisation of important organs is the cause of death in 95% of breast cancer.
  Developing, piloting and evaluating a theoretical-based intervention to support endocrine therapy medication taking behaviour in women with stage I-III breast cancer
  Prof K Bennett, Dr C Cahir
Applications accepted all year round

Funding Type

PhD Type

Almost 3,000 women are diagnosed with breast cancer annually in Ireland. In women with hormone-responsive early breast cancer, 5-10 years of endocrine therapy is recommended to prevent breast cancer recurrence and mortality, with a reduction in cancer recurrence of up to 50%.
  The role of USP11 in ER+ Breast Cancer
  Prof D O'Connor, Prof T Robson
Applications accepted all year round

Funding Type

PhD Type

De-regulated estrogen receptor (ER) function is a key feature of approximately 70% of breast cancers. Given that the tumourigenic properties of ER primarily lie in its function as a growth-controlling transcription factor, we sought to discover novel modulators of ER transcriptional activity.
  Decreasing the side effects from breast cancer treatment
  Dr M Aznar, Prof M Van Herk, Prof C West
Applications accepted all year round

Funding Type

PhD Type

Radiotherapy is an important part of a successful treatment for many women with breast cancer, but it can lead to side effects. Women often complain about skin burns, a stiff shoulder or a swollen arm.
  Combined targeting of PD-L1 and NFκB pathways to reverse T-cell exhaustion and restore anti-tumour immunity in breast cancer.
  Dr A Idris
Application Deadline: 1 July 2020

Funding Type

PhD Type

The majority of deaths from breast cancer following conventional therapies are a result of metastases. Programmed death 1 ligand (PD-L1), a negative regulator of the immune system, is highly expressed in triple negative breast tumours and cell lines, and its expression is associated with suppressed anti-tumour immunity.
  Targeting IL-1B to improve outcome for patients with breast cancer bone metastases.
  Dr P Ottewell
Application Deadline: 30 July 2020

Funding Type

PhD Type

Background. Breast cancer metastasis to bone is currently incurable. Treatment consists of combining anti-tumour therapies with bone strengthening agents such as zoledronic acid (ZA).
  Characterizing the heterogeneity of stem cells in the normal breast and breast tumours
  Dr A Ucar, Prof K R Brennan
Applications accepted all year round

Funding Type

PhD Type

Tissue-restricted stem cells are crucial in supporting the development and maintenance of normal tissues. This is also true for tumours, as only a small population of tumour cells, which are known as cancer stem cells, have the unique stemness features and tumour-initiating capacity.
  RET a novel therapeutic target to treat breast cancer brain metastasis
  Prof L Young, Dr A Hill
Applications accepted all year round

Funding Type

PhD Type

Metastatic disease recurrence occurs in up to 30% of breast cancer patients with approximately 20% of these tumours metastasising to the brain.
  FGFR signalling in breast cancer
  Dr A Chioni
Applications accepted all year round

Funding Type

PhD Type

Growth factors are used during development to convey messages that tell cells to divide, survive, migrate and adopt a particular fate.
  Characterisation of the role of the adhesion protein tensin 3 in breast cancer progression
  Dr E Rainero
Applications accepted all year round

Funding Type

PhD Type

Breast cancer arises from the transformation of mammary epithelial cells. In the healthy tissue, these grow as a single monolayer of cells delimiting an internal hollow lumen 2.
  Fueling chemotherapy resistance in triple-negative breast cancer
  Dr K Brown
Applications accepted all year round

Funding Type

PhD Type

Triple-negative breast cancer (TNBC) is a molecularly heterogeneous group of diseases defined by the lack of estrogen receptor (ER), progesterone receptor (PR) and absence of human epidermal growth factor receptor-2 (HER2) amplification.
  Understanding and minimizing radiation damage in breast tissues
  Dr M Sherratt, Miss C Kirwan, Prof S Cartmell
Applications accepted all year round

Funding Type

PhD Type

Human beings are subjected to many forms of radiation both natural (principally ultraviolet radiation [UVR]) and artificial (diagnostic and therapeutic X-rays).
  The role of the breast microenvironment in suppressing early cancer invasion
  Assoc Prof B Parker, Dr D Zanker
Applications accepted all year round

Funding Type

PhD Type

Ductal carcinoma in situ (DCIS) is a pre-invasive stage of breast cancer, whereby the tumour cells remain restrained by myoepithelial cells that surround breast ducts.
  Breast Cancer Omics and Modelling
  Dr C Francavilla, Prof R Breitling
Applications accepted all year round

Funding Type

PhD Type

Background and goals. Breast cancer is the major cause of death among women and 90% of deaths are caused by incurable metastasis.
  The functional characterization of the tumour suppressor gene CSMD1 in breast cancer
  Dr S Bell
Applications accepted all year round

Funding Type

PhD Type

CUB and Sushi multiple domains protein 1 (CSMD1) maps to 8p23, a region deleted in many cancers including breast cancer. Our previous work has established that CSMD1 is an independent prognostic marker in ductal breast cancer, with reduced expression associated with high tumour grade and poor survival1.
Show 10 15 30 per page


FindAPhD. Copyright 2005-2020
All rights reserved.